{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,2]],"date-time":"2026-11-02T17:09:59Z","timestamp":1793639399156,"version":"4.5.1"},"reference-count":40,"publisher":"Elsevier BV","issue":"1","license":[{"start":{"date-parts":[[2019,7,1]],"date-time":"2019-07-01T00:00:00Z","timestamp":1561939200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2019,7,1]],"date-time":"2019-07-01T00:00:00Z","timestamp":1561939200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","gynecologiconcology-online.net","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Gynecologic Oncology"],"published-print":{"date-parts":[[2019,7]]},"DOI":"10.1016\/j.ygyno.2019.04.010","type":"journal-article","created":{"date-parts":[[2019,4,13]],"date-time":"2019-04-13T01:15:28Z","timestamp":1555118128000},"page":"199-206","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":43,"title":["Constitutively active ESR1 mutations in gynecologic malignancies and clinical response to estrogen-receptor directed therapies"],"prefix":"10.1016","volume":"154","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-2174-3693","authenticated-orcid":false,"given":"St\u00e9phanie L.","family":"Gaillard","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kaitlyn J.","family":"Andreano","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Laurie M.","family":"Gay","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Meghan","family":"Steiner","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Matthew S.","family":"Jorgensen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Brittany Anne","family":"Davidson","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Laura J.","family":"Havrilesky","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Angeles","family":"Alvarez Secord","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fidel A.","family":"Valea","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gerardo","family":"Colon-Otero","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Deborah A.","family":"Zajchowski","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ching-Yi","family":"Chang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Donald P.","family":"McDonnell","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Andrew","family":"Berchuck","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Julia A.","family":"Elvin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.ygyno.2019.04.010_bb0005","doi-asserted-by":"crossref","first-page":"1439","DOI":"10.1038\/ng.2822","article-title":"ESR1 ligand-binding domain mutations in hormone-resistant breast cancer","volume":"45","author":"Toy","year":"2013","journal-title":"Nat. Genet."},{"key":"10.1016\/j.ygyno.2019.04.010_bb0010","doi-asserted-by":"crossref","first-page":"2961","DOI":"10.1200\/JCO.2016.67.3061","article-title":"Plasma ESR1 mutations and the treatment of estrogen receptor-positive advanced breast cancer","volume":"34","author":"Fribbens","year":"2016","journal-title":"J. Clin. Oncol."},{"key":"10.1016\/j.ygyno.2019.04.010_bb0015","article-title":"Accelerating discovery of functional mutant alleles in cancer","author":"Chang","year":"2017","journal-title":"Cancer Discov."},{"issue":"11579","key":"10.1016\/j.ygyno.2019.04.010_bb0020","article-title":"Heterogeneity and clinical significance of ESR1 mutations in ER-positive metastatic breast cancer patients receiving fulvestrant","volume":"7","author":"Spoerke","year":"2016","journal-title":"Nat. Commun."},{"key":"10.1016\/j.ygyno.2019.04.010_bb0025","doi-asserted-by":"crossref","first-page":"277","DOI":"10.1158\/2159-8290.CD-15-1523","article-title":"Activating ESR1 mutations differentially affect the efficacy of ER antagonists","volume":"7","author":"Toy","year":"2017","journal-title":"Cancer Discov."},{"key":"10.1016\/j.ygyno.2019.04.010_bb0030","doi-asserted-by":"crossref","first-page":"573","DOI":"10.1038\/nrclinonc.2015.117","article-title":"ESR1 mutations\u2014a mechanism for acquired endocrine resistance in breast cancer","volume":"12","author":"Jeselsohn","year":"2015","journal-title":"Nat. Rev. Clin. Oncol."},{"key":"10.1016\/j.ygyno.2019.04.010_bb0035","doi-asserted-by":"crossref","first-page":"6856","DOI":"10.1158\/0008-5472.CAN-13-1197","article-title":"D538G mutation in estrogen receptor-alpha: a novel mechanism for acquired endocrine resistance in breast cancer","volume":"73","author":"Merenbakh-Lamin","year":"2013","journal-title":"Cancer Res."},{"key":"10.1016\/j.ygyno.2019.04.010_bb0040","doi-asserted-by":"crossref","first-page":"1446","DOI":"10.1038\/ng.2823","article-title":"Activating ESR1 mutations in hormone-resistant metastatic breast cancer","volume":"45","author":"Robinson","year":"2013","journal-title":"Nat. Genet."},{"key":"10.1016\/j.ygyno.2019.04.010_bb0045","doi-asserted-by":"crossref","first-page":"1012","DOI":"10.1111\/j.1349-7006.2009.01145.x","article-title":"Estrogen receptor alpha gene ESR1 amplification may predict endocrine therapy responsiveness in breast cancer patients","volume":"100","author":"Tomita","year":"2009","journal-title":"Cancer Sci."},{"key":"10.1016\/j.ygyno.2019.04.010_bb0050","doi-asserted-by":"crossref","first-page":"3754","DOI":"10.1245\/s10434-017-5780-z","article-title":"Upregulation of the ESR1 gene and ESR ratio (ESR1\/ESR2) is associated with a worse prognosis in papillary thyroid carcinoma: the impact of the estrogen receptor alpha\/beta expression on clinical outcomes in papillary thyroid carcinoma patients","volume":"24","author":"Yi","year":"2017","journal-title":"Ann. Surg. Oncol."},{"key":"10.1016\/j.ygyno.2019.04.010_bb0055","first-page":"3775","article-title":"ESR1 gene amplification in endometrial carcinomas: a clinicopathological analysis","volume":"33","author":"Rahman","year":"2013","journal-title":"Anticancer Res."},{"key":"10.1016\/j.ygyno.2019.04.010_bb0060","doi-asserted-by":"crossref","first-page":"151","DOI":"10.1002\/path.2405","article-title":"Oestrogen receptor gene (ESR1) amplification is frequent in endometrial carcinoma and its precursor lesions","volume":"216","author":"Lebeau","year":"2008","journal-title":"J. Pathol."},{"key":"10.1016\/j.ygyno.2019.04.010_bb0065","doi-asserted-by":"crossref","first-page":"271","DOI":"10.1002\/path.2432","article-title":"ESR1 amplification in endometrial carcinomas: hope or hyperbole?","volume":"216","author":"Tan","year":"2008","journal-title":"J. Pathol."},{"key":"10.1016\/j.ygyno.2019.04.010_bb0070","doi-asserted-by":"crossref","first-page":"160","DOI":"10.5306\/wjco.v7.i2.160","article-title":"Estrogen receptor alpha gene amplification in breast cancer: 25\u202fyears of debate","volume":"7","author":"Holst","year":"2016","journal-title":"World J. Clin. Oncol."},{"key":"10.1016\/j.ygyno.2019.04.010_bb0075","doi-asserted-by":"crossref","first-page":"312","DOI":"10.1016\/j.ygyno.2016.03.006","article-title":"Estrogen receptor-alpha as a predictive biomarker in endometrioid endometrial cancer","volume":"141","author":"Backes","year":"2016","journal-title":"Gynecol. Oncol."},{"key":"10.1016\/j.ygyno.2019.04.010_bb0080","doi-asserted-by":"crossref","first-page":"347","DOI":"10.1111\/his.13071","article-title":"Molecular alterations in indolent, aggressive and recurrent ovarian low-grade serous carcinoma","volume":"70","author":"McIntyre","year":"2017","journal-title":"Histopathology"},{"issue":"5006","key":"10.1016\/j.ygyno.2019.04.010_bb0085","article-title":"Genomic analyses of gynaecologic carcinosarcomas reveal frequent mutations in chromatin remodelling genes","volume":"5","author":"Jones","year":"2014","journal-title":"Nat. Commun."},{"key":"10.1016\/j.ygyno.2019.04.010_bb0090","doi-asserted-by":"crossref","first-page":"818","DOI":"10.1158\/2159-8290.CD-17-0151","article-title":"AACR project GENIE: powering precision medicine through an international consortium","volume":"7","author":"Consortium APG","year":"2017","journal-title":"Cancer Discov."},{"key":"10.1016\/j.ygyno.2019.04.010_bb0095","doi-asserted-by":"crossref","first-page":"609","DOI":"10.1038\/nature10166","article-title":"Integrated genomic analyses of ovarian carcinoma","volume":"474","year":"2011","journal-title":"Nature"},{"key":"10.1016\/j.ygyno.2019.04.010_bb0100","doi-asserted-by":"crossref","first-page":"67","DOI":"10.1038\/nature12113","article-title":"Integrated genomic characterization of endometrial carcinoma","volume":"497","author":"Cancer Genome Atlas Research N","year":"2013","journal-title":"Nature"},{"key":"10.1016\/j.ygyno.2019.04.010_bb0105","article-title":"Integrated genomic and molecular characterization of cervical cancer","author":"Cancer Genome Atlas Research N","year":"2017","journal-title":"Nature"},{"key":"10.1016\/j.ygyno.2019.04.010_bb0110","doi-asserted-by":"crossref","first-page":"401","DOI":"10.1158\/2159-8290.CD-12-0095","article-title":"The cBio cancer genomics portal: an open platform for exploring multidimensional cancer genomics data","volume":"2","author":"Cerami","year":"2012","journal-title":"Cancer Discov."},{"key":"10.1016\/j.ygyno.2019.04.010_bb0115","doi-asserted-by":"crossref","first-page":"pl1","DOI":"10.1126\/scisignal.2004088","article-title":"Integrative analysis of complex cancer genomics and clinical profiles using the cBioPortal","volume":"6","author":"Gao","year":"2013","journal-title":"Sci. Signal."},{"key":"10.1016\/j.ygyno.2019.04.010_bb0120","doi-asserted-by":"crossref","first-page":"D805","DOI":"10.1093\/nar\/gku1075","article-title":"COSMIC: exploring the world's knowledge of somatic mutations in human cancer","volume":"43","author":"Forbes","year":"2015","journal-title":"Nucleic Acids Res."},{"key":"10.1016\/j.ygyno.2019.04.010_bb0125","series-title":"CONBRIZA (Bazedoxifene) [Summary of Product Characteristics]","year":"2014"},{"key":"10.1016\/j.ygyno.2019.04.010_bb0130","series-title":"FABLYN (Lasofoxifene) EMA Assessment Report","year":"2009"},{"key":"10.1016\/j.ygyno.2019.04.010_bb0135","series-title":"Faslodex (Fulvestrant) [Package Insert]","year":"2007"},{"key":"10.1016\/j.ygyno.2019.04.010_bb0140","series-title":"EVISTA (Raloxifene Hydrochloride) [Package Insert]","year":"2007"},{"key":"10.1016\/j.ygyno.2019.04.010_bb0145","doi-asserted-by":"crossref","first-page":"243","DOI":"10.1007\/s10549-013-2677-9","article-title":"Serum concentrations of tamoxifen and its metabolites increase with age during steady-state treatment","volume":"141","author":"Lien","year":"2013","journal-title":"Breast Cancer Res. Treat."},{"key":"10.1016\/j.ygyno.2019.04.010_bb0150","doi-asserted-by":"crossref","first-page":"2866","DOI":"10.1093\/annonc\/mdx490","article-title":"Hybrid capture-based genomic profiling of circulating tumor DNA from patients with estrogen receptor-positive metastatic breast cancer","volume":"28","author":"Chung","year":"2017","journal-title":"Ann. Oncol."},{"key":"10.1016\/j.ygyno.2019.04.010_bb0155","series-title":"Targeted Next-Generation Sequencing Reveals Clinically Actionable BRAF and ESR1 Mutations in Low-Grade Serous Ovarian Carcinoma","author":"Stover","year":"2018"},{"key":"10.1016\/j.ygyno.2019.04.010_bb0160","doi-asserted-by":"crossref","first-page":"313ra182","DOI":"10.1126\/scitranslmed.aac7551","article-title":"Analysis of ESR1 mutation in circulating tumor DNA demonstrates evolution during therapy for metastatic breast cancer","volume":"7","author":"Schiavon","year":"2015","journal-title":"Sci. Transl. Med."},{"key":"10.1016\/j.ygyno.2019.04.010_bb0165","doi-asserted-by":"crossref","first-page":"6823","DOI":"10.1158\/1078-0432.CCR-17-1260","article-title":"A phase II trial of neoadjuvant MK-2206, an AKT inhibitor, with anastrozole in clinical stage II or III PIK3CA-mutant ER-positive and HER2-negative breast cancer","volume":"23","author":"Ma","year":"2017","journal-title":"Clin. Cancer Res."},{"key":"10.1016\/j.ygyno.2019.04.010_bb0170","doi-asserted-by":"crossref","first-page":"85","DOI":"10.1016\/j.ygyno.2017.07.127","article-title":"Primary cytoreductive surgery and adjuvant hormonal monotherapy in women with advanced low-grade serous ovarian carcinoma: reducing overtreatment without compromising survival?","volume":"147","author":"Fader","year":"2017","journal-title":"Gynecol. Oncol."},{"issue":"60","key":"10.1016\/j.ygyno.2019.04.010_bb0175","article-title":"Mutation site and context dependent effects of ESR1 mutation in genome-edited breast cancer cell models","volume":"19","author":"Bahreini","year":"2017","journal-title":"Breast Cancer Res."},{"key":"10.1016\/j.ygyno.2019.04.010_bb0180","doi-asserted-by":"crossref","first-page":"993","DOI":"10.1158\/1078-0432.CCR-15-0943","article-title":"ESR1 mutations in circulating plasma tumor DNA from metastatic breast cancer patients","volume":"22","author":"Chu","year":"2016","journal-title":"Clin. Cancer Res."},{"key":"10.1016\/j.ygyno.2019.04.010_bb0185","doi-asserted-by":"crossref","first-page":"1023","DOI":"10.1038\/nbt.2696","article-title":"Development and validation of a clinical cancer genomic profiling test based on massively parallel DNA sequencing","volume":"31","author":"Frampton","year":"2013","journal-title":"Nat. Biotechnol."},{"key":"10.1016\/j.ygyno.2019.04.010_bb0190","doi-asserted-by":"crossref","first-page":"3004","DOI":"10.1182\/blood-2015-08-664649","article-title":"Integrated genomic DNA\/RNA profiling of hematologic malignancies in the clinical setting","volume":"127","author":"He","year":"2016","journal-title":"Blood"},{"key":"10.1016\/j.ygyno.2019.04.010_bb0195","doi-asserted-by":"crossref","first-page":"4721","DOI":"10.1210\/endo.142.11.8471","article-title":"Development of an ER action indicator mouse for the study of estrogens, selective ER modulators (SERMs), and xenobiotics","volume":"142","author":"Nagel","year":"2001","journal-title":"Endocrinology"},{"key":"10.1016\/j.ygyno.2019.04.010_bb0200","doi-asserted-by":"crossref","first-page":"22777","DOI":"10.1074\/jbc.270.39.22777","article-title":"Identification of a new subclass of Alu DNA repeats which can function as estrogen receptor-dependent transcriptional enhancers","volume":"270","author":"Norris","year":"1995","journal-title":"J. Biol. Chem."}],"container-title":["Gynecologic Oncology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0090825819305050?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0090825819305050?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,9,25]],"date-time":"2025-09-25T03:42:48Z","timestamp":1758771768000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0090825819305050"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2019,7]]},"references-count":40,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2019,7]]}},"alternative-id":["S0090825819305050"],"URL":"https:\/\/doi.org\/10.1016\/j.ygyno.2019.04.010","relation":{},"ISSN":["0090-8258"],"issn-type":[{"value":"0090-8258","type":"print"}],"subject":[],"published":{"date-parts":[[2019,7]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Constitutively active ESR1 mutations in gynecologic malignancies and clinical response to estrogen-receptor directed therapies","name":"articletitle","label":"Article Title"},{"value":"Gynecologic Oncology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.ygyno.2019.04.010","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2019 Elsevier Inc. All rights reserved.","name":"copyright","label":"Copyright"}]}}